Research Collaboration for Mekonos, Bit.bio to Advance Cell Engineering
This approach is defined as being used to express transcription factor combinations to reprogram human induced pluripotent stem cells (iPSCs).
Mekonos, Inc. announced a new research collaboration with bit.bio on May 4, 2023 to test and optimize non-viral delivery of bit.bio’s patented safe harbor gene-targeting approach. This approach is defined as being used to express transcription factor combinations to reprogram human induced pluripotent stem cells (iPSCs).
A gene-targeting route is meant to be an alternative for viral vector delivery, which will allow bit.bio to engineer stem cells into any mature, functional human cell type with higher efficiency, speed, and control, according to the press release.
“The combination of Mekonos’ unique, silicon chip-based delivery platform with bit.bio’s leading cellular reprogramming technologies will enable powerful new levels of precision and efficiency in the engineering of iPSCs,” said Jake Lesnik, VP of Business Development at Mekonos, in a press release. “We are excited to partner with the world-class team at bit.bio— leaders in synthetic biology and the engineering of human cells—and to leverage Mekonos’ unique non-viral platform for ex-vivo delivery of reprogramming factors to engineer human cells at unprecedented scale and efficiency.”
Source: Mekonos
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
